The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Combination Chemotherapy and Radiotherapy for Primary Central Nervous System Lymphoma: Radiation Therapy Oncology Group Study 93-10
Abstract
PURPOSE: Primary CNS lymphoma (PCNSL) is an aggressive primary brain tumor. Cranial irradiation alone rarely results in long-term disease control or prolonged survival. We prospectively studied the use of combination chemotherapy plus cranial irradiation in newly diagnosed patients with PCNSL. PATIENTS AND METHODS: We enrolled 102 newly diagnosed, immunocompetent patients with PCNSL; 98 were assessable. Patients first received five cycles of methotrexate 2.5 g/m 2, vincristine, procarbazine, and intraventricular methotrexate (12 mg). Whole-brain radiotherapy (RT) was administered to a total dose of 45 Gy and all patients received high-dose cytarabine after RT. RESULTS: Fifty-eight percent of patients with measurable disease had a complete response to preirradiation chemotherapy and 36% had a partial (> 50%) response, for a 94% response rate. Median progression-free survival was 24.0 months and overall survival was 36.9 months. Age was an important prognostic factor; median survival was 50.4 months in patients younger than 60 and only 21.8 months in those aged 60 or older (P < .001). Fifty-three percent of patients had grade 3 or 4 toxicity during induction chemotherapy, half of which was hematologic. However, 12 patients (15%) experienced severe delayed neurologic toxicity, eight of whom died. CONCLUSION: This is the first multicenter trial demonstrating improved survival with the combination of chemotherapy plus RT compared with previous reports of RT alone. A high-dose methotrexate-based regimen produced a high response rate before RT was administered. High-dose methotrexate combined with cranial irradiation is an effective therapeutic approach to PCNSL, but neurotoxicity is a delayed risk of this approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Nelson, D. F., Martz, K. L., Bonner, H., Nelson, J. S., Newall, J., Kerman, H. D., Thomson, J. W., & Murray, K. J. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90538-s · Cited by 635
Treatment for Primary CNS Lymphoma: The Next Step
Abrey, L. E., Yahalom, J., & DeAngelis, L. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3144 · Cited by 607
Self-citationLong-term survival in primary CNS lymphoma.
Abrey, L. E., DeAngelis, L. M., & Yahalom, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.859 · Cited by 577
Self-citationCombined modality therapy for primary CNS lymphoma.
DeAngelis, L. M., Yahalom, J., Thaler, H. T., & Kher, U. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.635 · Cited by 544
Self-citationMcAllister, L. D., Doolittle, N. D., Guastadisegni, P. E., Kraemer, D. F., Lacy, C. A., Crossen, J. R., & Neuwelt, E. A. (2000) · Neurosurgery · doi:10.1093/neurosurgery/46.1.51 · Cited by 239
Is Intrathecal Methotrexate Necessary in the Treatment of Primary CNS Lymphoma?
Khan, R. B., Shi, W., Thaler, H. T., DeAngelis, L. M., & Abrey, L. E. (2002) · Journal of Neuro-Oncology · doi:10.1023/a:1016077907952 · Cited by 186
Self-citationHerrlinger, U., Schabet, M., Brugger, W., Kortmann, R., Küker, W., Deckert, M., Engel, C., Schmeck‐Lindenau, H., Mergenthaler, H., Krauseneck, P., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10102 · Cited by 180
Hiraga, S., Arita, N., Ohnishi, T., Kohmura, E., Yamamoto, K., Oku, Y., Taki, T., Sato, M., Aozasa, K., & Yoshimine, T. (1999) · Journal of Neurosurgery · doi:10.3171/jns.1999.91.2.0221 · Cited by 158
Tetef, M. L., Margolin, K. A., Doroshow, J. H., Akman, S. A., Leong, L., Morgan, R. J., Raschko, J. W., Slatkin, N., Somlo, G., Longmate, J., et al. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000118 · Cited by 93
Cited by
Abrey, L. E., Batchelor, T. T., Ferreri, A. J. M., Gospodarowicz, M., Pulczynski, E. J., Zucca, E., Smith, J. R., Korfel, A., Soussain, C., DeAngelis, L. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.524 · Cited by 914
Self-citationFerreri, A. J., Reni, M., Foppoli, M., Martelli, M., Pangalis, G. A., Frezzato, M., Cabras, M. G., Fabbri, A., Corazzelli, G., Ilariucci, F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61416-1 · Cited by 662
Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy
Parhi, P., Mohanty, C., & Sahoo, S. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.010 · Cited by 573
Rubenstein, J. L., Hsi, E. D., Johnson, J. L., Jung, S.-H., Nakashima, M. O., Grant, B., Cheson, B. D., & Kaplan, L. D. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.9957 · Cited by 509
Morris, P. G., Correa, D. D., Yahalom, J., Raizer, J. J., Schiff, D., Grant, B., Grimm, S., Lai, R. K., Reiner, A. S., Panageas, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.4910 · Cited by 500
Self-citation
Metadata
- Authors
- DeAngelis, L. M., Seiferheld, W., Schold, S. C., Fisher, B., & Schultz, C. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-12-15
- Volume
- 20
- Issue
- 24
- Pages
- 4643-4648
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1994004225
- Cited by
- 738
- References
- 12
- FWCI
- 14.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.